Rosetta Genomics Granted US Patent for miRNA Used in Diagnostic Tests
May 12, 2011
Rosetta Genomics Granted US Patent for miRNA Used in Diagnostic Tests
The patent protects human hsa-miR-497, an "important component" of Rosetta's miRview Mets and miRview Mets2 diagnostic tests, used to identify the tissue of origin in cancers of unknown primary.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Genomics Terminates Deal with Avatao
July 17, 2012 / GenomeWeb Daily News - Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - Rosetta Genomics' 2012 Revenues Nearly Double
March 25, 2013 / GenomeWeb Daily News - People in the News: Ron Kalfus, Guy Malchi, Steve Miller
August 23, 2012 / Gene Silencing News - Rosetta Genomics Expects $27.7M in Net Proceeds from Public Offering
July 26, 2012 / GenomeWeb Daily News